Trials and programmes

Research saves lives

Search

FINESSE

BIG 2-13

Oral lucitanib for patients with FGFR1 ER+ metastatic breast cancer

OlympiA

BIG 6-13

Olaparib as adjuvant treatment in patients with germline BRCA-mutated high risk HER2 negative primary breast cancer (OlympiA)

PYTHIA

BIG 14-04

Palbociclib in molecularly characterised ER-positive/HER2-negative metastatic breast cancer

PANACEA

BIG 4-13

anti-PD-1 monoclonAl aNtibody in AdvanCed, trastuzumab-resistant, HER2-positive breAst cancer

DECRESCENDO

BIG 19-02

De-escalation of adjuvant chemotherapy in HER2-positive, HR-negative breast cancer

AMEERA-6

BIG 20-01

Amcenestrant in patients with HR+, HER2-negative/positive breast cancer who experienced toxicities with aromatase inhibitors

BIG 1-98 / IBCSG 18-98

BIG 1-98

Letrozole or tamoxifen in treating postmenopausal women with breast cancer

SOLD

BIG 1-10

The Synergism Or Long Duration (SOLD) study

ULTIMATE

BIG 16-01

Immunotherapy as neoadjuvant treatment in ER+/HER2-negative breast cancer

TREAT CTC

BIG 1-12

TRastuzumab treatment for HER2-negative early breast cancer in the presence of circulating tumor cells

SUPREMO

BIG 2-04

Selective Use of Postoperative Radiotherapy aftEr MastectOmy

SOFT / TEXT

BIG 2-02 / BIG 3-02

Testing different post-operative endocrine treatments for young women with hormone-sensitive breast cancer

SNAP

BIG 2-12

Evaluation of different schedules of nab-paclitaxel for metastatic breast cancer

LORELEI

BIG 3-13

Different regimes of letrozole (or letrozole + taselisib) in postmenopausal women with ER positive/HER2-negative, early stage breast cancer

FINESSE

BIG 2-13

Oral lucitanib for patients with FGFR1 ER+ metastatic breast cancer

BRAVO

BIG 5-13

Niraparib for patients with HER2-negative, germline BRCA mutation-positive breast cancer

SOLE

BIG 1-07

ontinuous versus intermittent letrozole following endocrine treatment for postmenopausal women with disease-free of hormone-receptor positive, node-positive early stage breast cancer

PENELOPE-B

BIG 1-13

Post-neoadjuvant palbociblib for patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk

PYTHIA

BIG 14-04

Palbociclib in molecularly characterised ER-positive/HER2-negative metastatic breast cancer

PALLAS

BIG 14-03

PALbociclib CoLlaborative Adjuvant Study

IBIS II

BIG 5-02

International Breast Cancer Intervention Study

MA.32 Metformin

BIG 5-11

Effect of metformin on recurrence and survival in early stage breast cancer

OlympiA

BIG 6-13

Olaparib as adjuvant treatment in patients with germline BRCA-mutated high risk HER2 negative primary breast cancer (OlympiA)

POLAR

BIG 18-02

Palbociclib for HR+ isolated local or regional recurrence of breast cancer

Male Breast Cancer

BIG 2-07

Clinical and Biological Characterization of Male Breast Cancer

Exceptional Responders

BIG 16-04

A global hunt for Exceptional Responders in the BIG network

Breast Cancer in Pregnancy

BIG 2-03

Prospective Register Study for Diagnosis and Treatment of Breast Cancer in Pregnancy

NeoALTTO

BIG 1-06

Comparison of dual HER2 inhibition (lapatinib, trastuzumab) plus chemotherapy before surgery versus single HER2-targeted therapy

MINDACT

BIG 3-04

Can addition of 70-gene signature to common clinical-pathological criteria safely spare patients from adjuvant chemotherapy?

HERA

BIG 1-01

Comparison of different regimes of trastuzumab for women with HER2-positive primary breast cancer

EXPERT

BIG 16-02

EXamining PErsonalised Radiation Therapy for low-risk early breast cancer

DCIS

BIG 3-07

A randomized phase III study of radiation doses and fractionation schedules in non-low risk Ductal Carcinoma In Situ (DCIS) of the breast

POSITIVE

BIG 8-13

Endocrine therapy interruption to enable conception for young women with ER+ breast cancer

AURORA

BIG 14-01

Aiming to understand the molecular aberrations in metastatic breast cancer

APPALACHES

BIG 18-01

Adjuvant palbociclib in elderly patients with breast cancer

APHINITY

BIG 4-11

Comparison of single-versus-dual anti-HER2 therapy (trastuzumab, pertuzumab) for patients with HER2-positive primary breast cancer

ALTTO

BIG 2-06

Adjuvant lapatinib and trastuzumab: sequence and combination for patients with HER2/ErbB2 positive primary breast cancer

ALEXANDRA IMpassion030

BIG 16-05

Comparison of adjuvant anti PD-L1 antibody (atezolizumab) plus chemotherapy versus chemotherapy alone in TNBC patients

ALPHABET

BIG 18-04

Alpelisib in PIK3CA mutated HER2-positive advanced breast cancer

Breast international group (BIG) – aisbl

Rue de Bretagne 20,
1200 Brussels, Belgium
VAT BE 0468 176 240
IBAN BE08 0689 0916 0213

Donations greater than or equal to € 40 / year receive a 45% tax reduction. This means your donation of €40 only costs you € 22.

Navigation

The Breast International Group is proud to adhere
to the Code of Ethics of the VEF-AERF

Co-funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.

Breast international group (BIG) - aisbl

Trials and programmes

Research saves lives

Status

Settings

Subtypes

Others

Search

Navigation